NICE gives green light to multiple sclerosis drug

  • NICE
  • 19 Feb 2020

  • curated by Pavankumar Kamat
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

National Institute for Health and Care Excellence (NICE) has recommended peginterferon beta-1a (Plegridy) as a treatment option for relapsing-remitting multiple sclerosis (MS) for routine use within NHS England.

Peginterferon beta-1a is recommended for the treatment of adults with relapsing-remitting MS, within its marketing authorisation. The drug has been licensed for the same since 2014.

The recommended dose for peginterferon beta-1a is 125 µg administered subcutaneously every two weeks. Clinical trial evidence has shown peginterferon beta-1a to slow disease progression and decrease the frequency of relapses compared with placebo. Indirect comparison of peginterferon beta-1a with other beta interferons and glatiramer acetate has shown comparable effectiveness; however, peginterferon beta-1a needs to be injected less frequently than other beta interferons.

NICE has determined the cost-effectiveness estimates for peginterferon beta-1a to be favourable for use within the NHS.

In May 2018, NICE had conducted a review of several MS drugs and was unable to make a recommendation on peginterferon beta-1a at that time. However, NICE has reversed its earlier decision after a separate appraisal.

"We are pleased that NICE has approved Plegridy for people with relapsing-remitting MS," said David Martin, Chief Executive Officer of Multiple Sclerosis Trust, the leading national charity for the condition that contributed throughout the appraisal process.